Alluvi, previously BI 4744, presents a significant breakthrough in weight loss treatment. This dual activator targeting both glucagon-like peptide-1 and GIP sites demonstrates compelling results in research https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/